PDF DatasheetHuman KNG1 / BDK / kininogen-1 Recombinant Protein Product Attributes
Product Type: Recombinant Protein
Recombinant KNG1 / BDK / kininogen-1 based upon sequence from: Human
Host: QP8809 protein expressed in E. coli.
Tag: His
Protein Construction: A DNA sequence encoding the Homo sapiens (Human) KNG1 / BDK / kininogen-1, was expressed in the hosts and tags indicated. Please select your host/tag option, above.
Application Notes: Please contact us for application specific information for QP8809.
Bioactivity Data: Untested
Full Length? Partial (see sequence information for more details).
Expression Region: Ser390 – Ser644
Amino Acid Sequence: SSRIGEIKEE TTVSPPHTSM APAQDEERDS GKEQGHTRRH DWGHEKQRKH NLGHGHKHER DQGHGHQRGH GLGHGHEQQH GLGHGHKFKL DDDLEHQGGH VLDHGHKHKH GHGHGKHKNK GKKNGKHNGW KTEHLASSSE DSTTPSAQTQ EKTEGPTPIP SLAKPGVTVT FSDFQDSDLI ATMMPPISPA PIQSDDDWIP DIQIDPNGLS FNPISDFPDT TSPKCPGRPW KSVSEINPTT QMKESYYFDL TDGLS
Purity: Greater than 90% as determined by SDS-PAGE.
Reconstitution Instructions:
Concentration of Human KNG1 / BDK / kininogen-1 Protein:
Endotoxin Levels: Not determined.
Buffer: Tris-based buffer, 50% glycerol
Storage Conditions: Store at -20C to -80C.
| Recombinant Human KNG1 / BDK / kininogen-1 Protein General Information | |
|---|---|
| Alternate Names | |
| KNG1; BDK; Kininogen-1; BDK; BK; KNG | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KNG1 |
| Entrez Gene ID | 3827 |
| Ensemble Gene ID | ENSG00000113889 |
| RefSeq Protein Accession(s) | NP_000884.1 |
| RefSeq mRNA Accession(s) | NM_000893.3, NM_001102416.2, NM_001166451.1 |
| UniProt ID(s) | P01042 |
| UniGene ID(s) | Hs.77741 |
| HGNC ID(s) | HGNC:6383 |
| COSMIC ID Link(s) | KNG1 |
| KEGG Gene ID(s) | hsa:3827 |
| PharmGKB ID(s) | PA225 |
| General Description of Recombinant Human KNG1 / BDK / kininogen-1 Protein. | |
| 1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. | |
Limitations and Performance Guarantee
This is a life science research product (for Research Use Only). This product is guaranteed to work for a period of two years when stored at -70C or colder, and one year when aliquoted and stored at -20C.
There are no reviews yet.